Document is current
Any future updates will be listed below
-
Authors
Liu, Yusheng
Wang, Yizun https://orcid.org/0009-0009-3002-8315
Ko, Kyungwon https://orcid.org/0000-0002-4573-3668
Liu, Yuan
Huang, Haiyi
Wang, Yueji https://orcid.org/0000-0003-1908-7874
Zhou, Jiadiao
Baskaran, Dhyanesh
Han, Joonsu
Bhatta, Rimsha
Nguyen, Daniel
Leal, Cecilia https://orcid.org/0000-0001-5972-508X
Berry, Matthew R.
Lam, Fan https://orcid.org/0000-0002-4124-0663
Wang, Hua https://orcid.org/0000-0002-1157-8786
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA274738)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA270872)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA274738)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA270872)
National Science Foundation (DMR 21-43673 CAR)
National Science Foundation (DMR 21-43673 CAR)
Sontag Foundation
American Cancer Society
- License Information
-
More Information
Article History
Received: 31 January 2025
Accepted: 11 March 2026
First Online: 21 March 2026
Competing interests
: H.W. and Y.L. have filed a patent application (No. 63/402,413) for the red blood cell metabolic labeling and targeting technology. Other authors declare no competing interests.
